Focused On-demand Library for Major facilitator superfamily domain-containing protein 8

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8NHS3

UPID:

MFSD8_HUMAN

Alternative names:

Ceroid-lipofuscinosis neuronal protein 7

Alternative UPACC:

Q8NHS3; B2RDM1; B7Z205; Q8N2P3

Background:

Major facilitator superfamily domain-containing protein 8, also known as Ceroid-lipofuscinosis neuronal protein 7, plays a crucial role in the transport of small solutes across membranes, leveraging chemiosmotic ion gradients. This protein's involvement in cellular transport mechanisms highlights its fundamental role in maintaining cellular homeostasis and function.

Therapeutic significance:

The protein is directly associated with diseases such as Ceroid lipofuscinosis, neuronal, 7, and Macular dystrophy with central cone involvement, both of which have profound impacts on neurological and visual health. Understanding the role of Major facilitator superfamily domain-containing protein 8 could open doors to potential therapeutic strategies for these debilitating conditions.